Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

GlobalData: Ultra-Rapid-Acting Insulin Formulations Will Revolutionize Type 1 Diabetes Treatment Market by 2019

By Pharmaceutical Processing | October 7, 2014

Ultra-rapid formulations of the currently marketed rapid-acting insulin analogs have the clear potential to radically change the insulin market over the next five years, according to a director with research and consulting firm GlobalData.

Valentina Gburcik, Ph.D., GlobalData’s Director of Cardiovascular & Metabolic Disorders, states that the use of long-acting insulin analogs may decrease as rapid- and ultra-rapid-acting analogs gradually take over the type 1 diabetes market.

Gburcik explains: “A substantial and ongoing rise in insulin pump usage over recent years, alongside the rapid development of a closed-loop system, or artificial pancreas, strengthens the need for insulins that act even faster than the currently marketed rapid-acting analogs.

“An artificial pancreas, which combines continuous glucose monitoring, a control algorithm and an insulin pump device, will likely become reality over the next few years. Ultra-rapid-acting formulations will also help with developing artificial pancreas systems, as their fast reaction time could allow the pumps’ algorithms to dose insulin in real time.”

The director notes that a number of these formulations are currently in development and may profit from the increasing pump therapy use, as they better match the physiological profile of prandial insulin.

Gburcik says: “Novo Nordisk’s FIAsp (NN-1218) is an ultra-rapid-acting formulation of NovoLog/NovoRapid (insulin aspart), which aims to continue NovoLog’s legacy and protect the franchise from generic erosion to biosimilars, as the drug’s patent expires throughout 2014 and 2015.

“In addition, biotech companies Adocia, Biodel, and Halozyme Therapeutics are developing similar formulations that will likely reach the market over the next few years, due to the short duration of the pharmacokinetic/pharmacodynamic clinical studies that are necessary for these drugs.”

The director adds that while Adocia’s BioChaperon insulin lispro is the most developed of the three biotech offerings, the company will have to either raise more capital or enter into licensing or collaboration agreements with experienced and well-funded players to compete in the insulin market.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE